NeurAxon To Focus On Migraine With Aura For Potential First-In-Class nNOS Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
A Phase II trial of NXN-188 missed the primary endpoint in migraine, but a post hoc analysis showed stronger efficacy in patients with history of aura.